- Datum24.06.2024
- Uhrzeit19:00 - 20:00 Uhr
- Veranstalter
BNP Paribas
Du willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen![stock3 Terminal Chart](/img/banner/chart-light.png)
CureVac N.V. Namensaktien o.N. Kurse
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
L&S | VK | |||||
Tradegate | VK | |||||
Stuttgart | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Wertentwicklung (Nasdaq)
Wikifolio
Passender Service zu CureVac N.V. Namensaktien o.N.
Webinar zu CureVac N.V. Namensaktien o.N.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)2,215-12,360
- Jahrestief / Hoch ($)2,215-5,280
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von CureVac N.V. Namensaktien o.N.
Termine von CureVac N.V. Namensaktien o.N.
Beschreibung
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GSK to develop a second-generation covid vaccine. CureVac's first attempt to develop a covid vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.